Tegafur
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| (RS)-5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Identifiers | |
| CAS number | 17902-23-7 |
| ATC code | L01BC03 |
| PubChem | CID 288216 |
| ChemSpider | 254191 |
| UNII | 1548R74NSZ |
| KEGG | D01244 |
| ChEMBL | CHEMBL20883 |
| Synonyms | 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione |
| Chemical data | |
| Formula | C8H9FN2O3 |
| Mol. mass | 200.16 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Tegafur (INN) is a chemotherapeutic fluorouracil prodrug used in the treatment of cancers. It is a component of the combination drug tegafur-uracil. When metabolized, it becomes 5-fluorouracil.[1]
[edit] References
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |